Caxton Associates LP Invests $43,000 in Nuvation Bio Inc. (NYSE:NUVB)

Caxton Associates LP bought a new stake in shares of Nuvation Bio Inc. (NYSE:NUVB) during the 2nd quarter, HoldingsChannel reports. The institutional investor bought 14,558 shares of the company’s stock, valued at approximately $43,000.

Several other large investors have also added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in shares of Nuvation Bio by 3.0% during the 1st quarter. Vanguard Group Inc. now owns 7,534,148 shares of the company’s stock worth $27,424,000 after buying an additional 219,533 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Nuvation Bio by 551.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,354,632 shares of the company’s stock worth $4,932,000 after acquiring an additional 1,146,794 shares in the last quarter. Acadian Asset Management LLC grew its holdings in Nuvation Bio by 81.9% in the first quarter. Acadian Asset Management LLC now owns 1,174,464 shares of the company’s stock worth $4,273,000 after purchasing an additional 528,660 shares during the period. Dimensional Fund Advisors LP increased its stake in Nuvation Bio by 415.2% in the second quarter. Dimensional Fund Advisors LP now owns 1,018,329 shares of the company’s stock valued at $2,975,000 after purchasing an additional 820,669 shares in the last quarter. Finally, Octagon Capital Advisors LP acquired a new position in shares of Nuvation Bio during the fourth quarter valued at about $1,510,000. Institutional investors and hedge funds own 61.67% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on NUVB shares. HC Wainwright decreased their target price on Nuvation Bio from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, September 16th. Royal Bank of Canada restated an “outperform” rating and set a $5.00 price objective on shares of Nuvation Bio in a report on Tuesday, August 6th. Finally, Wedbush reiterated an “outperform” rating and issued a $5.00 target price on shares of Nuvation Bio in a report on Wednesday, September 11th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Nuvation Bio has a consensus rating of “Buy” and a consensus price target of $6.40.

Nuvation Bio Stock Performance

Shares of NUVB opened at $2.39 on Friday. The firm has a market capitalization of $595.68 million, a P/E ratio of -7.71 and a beta of 1.38. Nuvation Bio Inc. has a 52 week low of $0.95 and a 52 week high of $4.16. The stock has a 50 day moving average price of $3.02 and a two-hundred day moving average price of $3.01.

Nuvation Bio (NYSE:NUVB) last announced its quarterly earnings results on Monday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.09). The company had revenue of $1.44 million during the quarter. On average, equities analysts forecast that Nuvation Bio Inc. will post -0.4 earnings per share for the current year.

Nuvation Bio Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.